NasdaqCM:IMUX

Stock Analysis Report

Executive Summary

Immunic, Inc., a clinical-stage biopharmaceutical company developing a pipeline of selective oral immunology therapies for treating chronic inflammatory and autoimmune diseases, including ulcerative colitis, Crohn’s disease, relapsing-remitting multiple sclerosis, and psoriasis.

Snowflake

Fundamentals

Flawless balance sheet and overvalued.

Risks

  • Immunic has significant price volatility in the past 3 months.
  • Immunic is covered by less than 3 analysts.

Share Price & News

How has Immunic's share price performed over time and what events caused price changes?


Latest Share Price and Events


Market Performance


7 Day Return

3.1%

NasdaqCM:IMUX

0.4%

US Biotechs

1.2%

US Market


1 Year Return

n/a

NasdaqCM:IMUX

-10.8%

US Biotechs

1.7%

US Market

No trading data on IMUX.

No trading data on IMUX.


Share holder returns

IMUXIndustryMarket
7 Day3.1%0.4%1.2%
30 Day5.3%0.3%4.9%
90 Day56.3%1.6%3.7%
1 Yearn/a-10.1%-10.8%3.9%1.7%
3 Yearn/a7.3%3.6%47.2%37.7%
5 Yearn/a2.9%-2.0%60.0%42.4%

Price Volatility Vs. Market

How volatile is Immunic's share price compared to the market and industry in the last 5 years?


Simply Wall St News

Valuation

Is Immunic undervalued based on future cash flows and its price relative to the stock market?

2.05x

Price to Book (PB) ratio


Intrinsic Value Based on Future Cash Flows

Unable to calculate intrinsic value for Immunic to establish if it is available at moderate discount.

Unable to calculate intrinsic value for Immunic to establish if it is available at substantial discount.


Price Based on Earnings

Immunic is loss making, we can't compare its value to the US Biotechs industry average.

Immunic is loss making, we can't compare the value of its earnings to the United States of America market.


Price Based on Expected Growth

Unable to calculate PEG ratio for Immunic, we can't assess if its growth is good value.


Price Based on Value of Assets

Immunic is good value based on assets compared to the US Biotechs industry average.


Next Steps

Future Growth

How is Immunic expected to perform in the next 1 to 3 years based on estimates from 2 analysts?

22.3%

Forecasted Pharmaceuticals & Biotech industry annual growth in earnings


In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as Immunic has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.

This is quite a rare situation as 97% of companies covered by SimplyWall St do have past financial data.


Next Steps

Past Performance

How has Immunic performed over the past 5 years?

-163.1%

Last years earnings growth


Earnings and Revenue History


Past Earnings Growth Analysis

Immunic does not make a profit and there is insufficient past data to establish if their 5 year on year earnings growth rate was positive.

Unable to compare Immunic's 1-year earnings growth to the 5-year average as it is not currently profitable.

Unable to compare Immunic's 1-year growth to the US Biotechs industry average as it is not currently profitable.


Return on Equity

It is difficult to establish if Immunic has efficiently used shareholders’ funds last year (Return on Equity greater than 20%) as it is loss-making.


Return on Assets

It is difficult to establish if Immunic has efficiently used its assets last year compared to the US Biotechs industry average (Return on Assets) as it is loss-making.


Return on Capital Employed

It is difficult to establish if Immunic improved its use of capital last year versus 3 years ago (Return on Capital Employed) as it is currently loss-making.


Next Steps

Financial Health

How is Immunic's financial position?


Financial Position Analysis

Immunic is able to meet its short term (1 year) commitments with its holdings of cash and other short term assets.

Immunic's cash and other short term assets cover its long term commitments.


Debt to Equity History and Analysis

Immunic has no debt.

Immunic has not taken on any debt in the past 5 years.


Balance Sheet

Low level of unsold assets.

Immunic has no debt, it does not need to be covered by short term assets.


Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

Immunic has sufficient cash runway for 1.7 years based on current free cash flow.

Immunic has sufficient cash runway for 1.1 years if free cash flow continues to grow at historical rates of 45.9% each year.


Next Steps

Dividend

What is Immunic's current dividend yield, its reliability and sustainability?


Dividend Yield and Payments Analysis

Unable to evaluate Immunic's dividend yield against the bottom 25% of dividend payers as the company has not reported any payouts.

Unable to evaluate Immunic's dividend against the top 25% market benchmark as the company has not reported any payouts.

Unable to perform a dividend volatility check as Immunic has not reported any payouts.

Unable to verify if Immunic's dividend has been increasing as the company has not reported any payouts.


Current Payout to Shareholders

Unable to calculate sustainability of dividends as Immunic has not reported any payouts.


Future Payout to Shareholders

Insufficient estimate data to determine if a dividend will be paid in 3 years and that it will be sustainable.


Next Steps

Management

What is the CEO of Immunic's salary, the management and board of directors tenure and is there insider trading?

2.7yrs

Average management tenure


CEO

Daniel Vitt (51yo)

2.7yrs

Tenure

0

Dr. Daniel Vitt, PhD has been the Chief Executive Officer of Immunic AG since January 1, 2017 and also its President. Dr. Vitt served as Managing Director of 4SC Discovery GmbH. Dr. Vitt Co-founded 4SC AG  ...


Management Age and Tenure

2.7yrs

Average Tenure

The tenure for the Immunic management team is about average.


Board Age and Tenure

2.7yrs

Average Tenure

51yo

Average Age

The average tenure for the Immunic board of directors is less than 3 years, this suggests a new board.


Insider Trading

No 3 month open market individual insider trading information.


Ownership Breakdown


Management Team

  • Daniel Vitt (51yo)

    CEO, President & Director

    • Tenure: 2.7yrs
  • Manfred Gröppel

    Co-Founder & COO

    • Tenure: 0yrs
  • Andreas Mühler (56yo)

    Co-Founder and Chief Medical Officer

    • Tenure: 0yrs
  • Hella Kohlhof

    Chief Scientific Officer

    • Tenure: 2.7yrs
  • Jessica Breu

    Manager IR and Communications

    • Tenure: 0yrs
  • Sanjay Patel

    Chief Financial Officer

    • Tenure: 0.2yrs

Board Members

  • Joerg Neermann (52yo)

    • Tenure: 3.7yrs
  • Daniel Vitt (51yo)

    CEO, President & Director

    • Tenure: 2.7yrs
  • Vincent Ossipow (51yo)

    Director

    • Tenure: 2.7yrs
  • Duane Nash (48yo)

    Chairman

    • Tenure: 0.7yrs
  • Jan Van den Bossche

    Director

    • Tenure: 2.7yrs

Company Information

Immunic, Inc.'s company bio, employee growth, exchange listings and data sources


Key Information

  • Name: Immunic, Inc.
  • Ticker: IMUX
  • Exchange: NasdaqCM
  • Founded:
  • Industry: Biotechnology
  • Sector: Pharmaceuticals & Biotech
  • Market Cap: US$143.529m
  • Shares outstanding: 10.09m
  • Website: https://www.immunic-therapeutics.com

Number of Employees


Location

  • Immunic, Inc.
  • 11440 West Bernardo Court
  • Suite 300
  • San Diego
  • California
  • 92127
  • United States

Listings

TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
IMUXNasdaqCM (Nasdaq Capital Market)YesCommon StockUSUSDApr 2019
10VADB (Deutsche Boerse AG)YesCommon StockDEEURApr 2019

Biography

Immunic, Inc., a clinical-stage biopharmaceutical company developing a pipeline of selective oral immunology therapies for treating chronic inflammatory and autoimmune diseases, including ulcerative coliti ...


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2019/09/15 00:48
End of Day Share Price2019/09/13 00:00
Earnings2019/06/30
Annual Earnings2018/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.